Randomized Trial: SGLT2 inhibitor Reduces Progression of Kidney Disease in Patients with Type 2 Diabetes and Nephropathy

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy – New England Journal of Medicine (free for a limited period)

Commentary: Canagliflozin may offer renal protection in people with type 2 diabetes and CKD – Medicine Matters (free)

“among 1000 patients treated for 2.5 years, 21.2 individuals would need to be treated to prevent the composite primary outcome.” (from Medicine Matters)